Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model
about
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunityCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyA2aR antagonists: Next generation checkpoint blockade for cancer immunotherapyControl of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.The roles of CD73 in cancerTargeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacyCo-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis.The Chemical Constituents and Pharmacological Actions of Cordyceps sinensis.CD73: A potential biomarker for anti-PD-1 therapyTrial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Targeting PD-1/PD-L1 in lung cancer: current perspectives.The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.Barriers to Radiation-Induced In Situ Tumor Vaccination.A covalent antagonist for the human adenosine A2A receptor.Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers.Targeting adenosine for cancer immunotherapy.
P2860
Q26862220-087F36CF-F987-45F4-B733-EBB33AF660DCQ28066199-BCD1EEE3-391D-4DD9-80B3-C3C6958EC07CQ28087576-14C662DE-6F15-4E97-82A2-11DF332DAAE6Q29994573-FABADCDA-7F58-4A33-A0F3-F1F969BD47CAQ33763266-564FBBB8-D159-4F2A-AC7B-312465FB2CE9Q34003164-C1730988-A9A9-4050-A021-0878878AC765Q34550649-D4135548-3FDE-4369-9521-53FBBE237310Q34936598-E030B266-1531-48FA-9CE0-D9F20DA95100Q35556660-1FBF14BC-336D-49F8-890A-4225EBAB8EDEQ36107945-CC2DF4AB-211D-4B81-A26F-36448F53BD36Q37079141-0BAC14A1-9B1C-4D1B-B5F1-70AABCCCA3A6Q38956294-75100E8E-FE28-4270-AC85-DFE395EF4E30Q39161005-281C27D3-47EC-4AEE-90A3-A5F171770495Q39203685-A419E13D-90F2-4870-B383-58313B27183AQ41763691-7B319B94-2B23-4576-ABE3-8697AB9FF449Q46026307-1E485C44-B00A-4ED7-B634-FB83ABE6840EQ46047154-6831BB07-4293-4400-BB19-94005DD82F7DQ47131425-D185B824-68DD-4B11-BFB5-ED0C2488EDDAQ55001315-B2796900-92EA-4F01-8095-AD4E8B3DC467Q55330380-24CC760B-2618-45C1-879C-0C39D95BF338
P2860
Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adenosine limits the therapeut ...... mAb in a mouse melanoma model
@en
Adenosine limits the therapeut ...... mAb in a mouse melanoma model.
@nl
type
label
Adenosine limits the therapeut ...... mAb in a mouse melanoma model
@en
Adenosine limits the therapeut ...... mAb in a mouse melanoma model.
@nl
prefLabel
Adenosine limits the therapeut ...... mAb in a mouse melanoma model
@en
Adenosine limits the therapeut ...... mAb in a mouse melanoma model.
@nl
P2093
P2860
P1476
Adenosine limits the therapeut ...... mAb in a mouse melanoma model
@en
P2093
Aldo Pinto
Lucio Miele
Piera Maiolino
Raffaella Iannone
Silvana Morello
P2860
P304
P577
2014-03-01T00:00:00Z